Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.22 | 0.87 | 1.07 | -1.15 |
| FCF Yield | 4.07% | 2.81% | 2.82% | 2.89% |
| EV / EBITDA | 21.77 | 31.36 | 43.24 | 59.06 |
| Quality | ||||
| ROIC | 12.48% | 6.82% | 8.99% | 4.96% |
| Gross Margin | 98.56% | 97.90% | 98.44% | 98.74% |
| Cash Conversion Ratio | 1.74 | 1.56 | 2.20 | 2.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.52% | 18.52% | 12.49% | 12.88% |
| Free Cash Flow Growth | 54.09% | 11.99% | 38.52% | 7.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 0.43 | 0.00 | 0.72 |
| Interest Coverage | 4.51 | 54.54 | 35.07 | 3.97 |
| Efficiency | ||||
| Inventory Turnover | 0.59 | 1.04 | 0.66 | 0.47 |
| Cash Conversion Cycle | -490.43 | -788.46 | -420.78 | -476.28 |